Regeneron Pharmaceuticals, Inc.
Explore Regeneron Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Regeneron Pharmaceuticals, Inc.
Explore Regeneron Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Business Model Analysis
Annual Revenue: $14.34B
Regeneron makes money from direct product sales and collaboration revenue. U.S. EYLEA and EYLEA HD sales, global Libtayo sales, rare-disease medicines, Sanofi profit-share economics for Dupixent, and Bayer EYLEA collaboration revenue are the main pillars.
Regeneron's growth strategy centers on defending ophthalmology, scaling Dupixent economics, expanding Libtayo and oncology combinations, and selectively acquiring or partnering for new modalities.
Regeneron makes money from U.S. product sales, global product sales, and collaboration revenue from partners such as Sanofi and Bayer.
Regeneron sells and develops medicines for eye disease, immunology, oncology, rare disease, and genetic medicine.
Regeneron ultimately serves patients, physicians, payers, hospitals, specialty pharmacies, distributors, and collaboration partners.
Regeneron's biggest risk is concentration in EYLEA and Dupixent economics while biosimilars, pricing pressure, and pipeline setbacks can change growth quickly.